INRLF News and Press, Valneva Se Ord From 09/25/23

Saint Herblain ( France), September 25 , 202 3 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the signing of a new $32 million contract with the United States (U.S.) Department of Defense (DoD) for the supply of ...

2023-09-21 13:06:04 ET Valneva SE (VALN) Q2 2023 Earnings Conference Call September 21, 2023, 09:00 AM ET Company Participants Joshua Drumm - VP, IR Thomas Lingelbach - CEO Peter Buhler - CFO Conference Call Participants Maury Raycroft - Jefferies ...

Product sales more than doubled in the first half of 202 3 to €69.7 million compared to €33.3 million in the first half of 2022 Driven by IXIARO ® and DUKORAL ® sales, both of which benefited from a continued recovery...

S trong immune response shown in both children and adolescents one month after booster dose ( m onth 19) in VLA15-221 study P reviously observed high anamnestic antibody response in adults confirmed VLA15 well-tolerated in all ag...

Saint- Herb lain (France ) , August 31 , 2 02 3 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that members of its senior leadership team are scheduled to participate in 1-on-1 meetings with i...

Saint - Herblain ( France), August 29 , 2 02 3 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that Health Canada has completed screening validation of the Company’s regulatory application f...

Saint- Herb lain (France ) , August 28 , 2 02 3 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported positive initial Phase 3 safety data in adolescents for its single-dose chikungunya virus (CHI...

Up to an additional $100 million made available in two tranches Saint - Herblain ( France ), August 1 7 , 202 3 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced an agreement to incre...

Saint - Herblain ( France), August 14 , 2 02 3 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the U.S. Food and Drug Administration (FDA) has revised the Prescription Drug User Fee Act (PDUFA...

2023-07-18 04:17:27 ET Summary Positive Phase 3 data from Bavarian Nordic's chikungunya virus (CHIKV) vaccine candidate, PXVX0317, reinforces bullish view on Valneva's VLA1553 due to its superior clinical profile. Valneva's VLA1553 demonstrated impressive seroresponse rates and du...